7-Chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol | 95191-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 7-Chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol
• 英文别名: 8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
• CAS: 95191-55-2
• 化学式: C₁₇H₁₈ClNO
• 分子量: 287.8
• InChiKey: GOTMKOSCLKVOGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-Chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol 、 异氰酸乙酯 生成 (8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl) N-ethylcarbamate
  参考文献：
  名称：

  GOLD, E. H.;CHANG, WEI, K.

  摘要：

  DOI：
• 作为产物：
  描述：

  8-Chloro-7-methoxy-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine 生成 7-Chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol
  参考文献：
  名称：

  GOLD, E. H.;CHANG, WEI, K.

  摘要：

  DOI：

文献信息

• Substituted 2-aminotetralins
  申请人：Whitby Research, Inc.

  公开号：US05274003A1

  公开（公告）日：1993-12-28

  Optically active or racemic compounds are provided having the formula ##STR1## where R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H and OH with the provision that at least one of R.sub.2, R.sub.3 and R.sub.4 is H, that R.sub.2 and R.sub.4 are not both OH; X is oxygen; and R.sub.1 is selected from the group consisting of ##STR2## wherein Z is oxygen, nitrogen or sulfur, wherein Y is selected from the group consisting of hydroxy, nitro, cyano, azido, amino, acylamino, carboxyamido, trifluoromethyl, sulfate, sulfonamido, halogen, hydrocarbyl and heteroatom-substituted hydrocarbyl radicals, wherein said heteroatoms are selected from the group consisting of halogen, nitrogen, oxygen, sulfur and phosphorus and said hydrocarbyl radicals comprise from 1 to 12 carbon atoms, and a is an integer of from zero to 3. These compounds are capable of binding selectivity of one or more dopamine D.sub.2 receptors, for instance, in humans. They are useful in treatment of disorders of the central nervous, cardiovascular, and endocrine systems, such as elevated intraocular pressure, schizophrenia and Parkinsonism, and for inducing anorexia and weight loss in humans and other mammals.

  提供具有以下式子的旋光性或外消旋化合物：##STR1## 其中R.sub.2、R.sub.3和R.sub.4分别选择自H和OH的组，但至少其中一个为H，且R.sub.2和R.sub.4不同时为OH；X为氧；R.sub.1选择自下列组：##STR2## 其中Z为氧、氮或硫，Y选择自羟基、硝基、氰基、叠氮基、氨基、酰胺基、羧酸胺基、三氟甲基、硫酸酯、磺酰胺基、卤素、烃基和取代烃基基团，其中所述的杂原子选择自卤素、氮、氧、硫和磷的组，所述的烃基基团包含1至12个碳原子，且a为0至3的整数。这些化合物能够选择性地结合一种或多种多巴胺D.sub.2受体，例如在人体中。它们在治疗中枢神经、心血管和内分泌系统的疾病方面有用，例如高眼压、精神分裂症和帕金森病，并可诱导人类和其他哺乳动物的厌食和减重。
• Benzazepine derivatives, pharmaceutical compositions containing them and processes for the preparation of such compounds and compositions
  申请人：SCHERING CORPORATION

  公开号：EP0135767A1

  公开（公告）日：1985-04-03

  Substituted 8-amino-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepines useful in the treatment of mental disorders such as schizophrenia and depression, and having activities of prolonged duration, are disclosed. Methods for preparing these compounds and methods for their use are also described.

  本发明公开了可用于治疗精神障碍（如精神分裂症和抑郁症）且活性持续时间长的取代型 8-氨基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓。还描述了制备这些化合物的方法及其使用方法。
• 2,3,4,5-tetrahydro-1H-3-benzazepines substituted in position 5
  申请人：NOVO NORDISK A/S

  公开号：EP0200455A2

  公开（公告）日：1986-11-05

  Novel 2,3,4,5-tetrahydro-1H-3-benzazepines which in the 5-position have furyl, thienyl, pyridyl, or ring systems consisting of phenyl ortho condensed with a benzen. cyclohexan, cyclohexen, cyclopentan or cyclopenten ring wherein one of the carbon atoms may be exchanged with oxygen, sulphur or nitrogen, have interesting central and cardiovascular effects.

  新型 2,3,4,5-四氢-1H-3-苯并氮杂卓在 5 位上具有呋喃基、噻吩基、吡啶基，或由苯基正交缩合苯环、环己烷环、环己烯环、环戊烷环或环戊烯环组成的环系统，其中一个碳原子可以与氧、硫或氮交换，具有有趣的中枢和心血管效应。
• ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE- ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：EP3782698A1

  公开（公告）日：2021-02-24

  In various embodiments, methods are provided for applying transcutaneous and/or epidural spinal cord stimulation with and without selective pharmaceuticals to restore voluntary control of hand function in tetraplegic subjects.

  在各种实施方案中，提供了使用或不使用选择性药物的经皮和/或硬膜外脊髓刺激方法，以恢复四肢瘫痪者对手部功能的自主控制。
• Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10137299B2

  公开（公告）日：2018-11-27

  In various embodiments, methods are provided for applying transcutaneous and/or epidural spinal cord stimulation with and without selective pharmaceuticals to restore voluntary control of hand function in tetraplegic subjects.

  在各种实施方案中，提供了使用或不使用选择性药物的经皮和/或硬膜外脊髓刺激方法，以恢复四肢瘫痪者对手部功能的自主控制。